Chunde Capital
辰德资本
elsewhere's corpus does not cover Chunde Capital as a subject in its own right. The name appears only as a background participant in funding rounds for other companies — notably as a lead or co-lead investor in Qiheshengke Biotechnology's Pre-A round in 2023 and Pipi Bear's Series A in 2026 , and as a follow-on investor in Qiheshengke's later rounds — but no retrieved material profiles the fund itself, its founding, team, strategy, or assets under management.
AI-generated — may contain errors, please verify.
Coverage
MaKe (Code Engraving) | Senior Robotics Firm "Pipi Bear" Closes Tens of Millions of RMB in Series A Funding, Focusing on Elderly Lifestyle Service Scenarios
Low-speed electric vehicles, sales volume ranked #1 nationwide
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Qihe Biotech Closes Over RMB 200 Million Series A to Accelerate Gene Editing R&D and Commercialization
Develop novel gene-editing technologies to create exceptional biological traits and products.
Chip/Consumer Electronics/Gene Editing Firms Raise New Funding; Quantum Computers, Micro-Display Chips Achieve Global Leadership | Rongbao · April
Targeting international advanced standards.
Qihe Biotech Closes Over 100 Million Yuan Pre-A Round to Accelerate Development and Application of Novel Gene-Editing Technologies
Accelerate the commercialization of gene-edited breeding.
Qiheshengke Biotechnology Raises Over 100 Million RMB in Pre-A Round with Source Code Capital Participation
This round of funding will help Qiheshengke Biotechnology accelerate the commercialization of gene-edited bio-breeding.
